"CONTRIBUTION**What are the novel findings of this work?**The impaired (head) growth that is encountered in fetuses with a congenital heart defect (CHD) is more likely explained by the presence of placenta‐related pathology and genetic anomaly than as an effect of alteration in fetal hemodynamics caused by the CHD itself.**What are the clinical implications of this work?**Future research on brain development in CHD fetuses, in relation to overall growth and additional pathology, is required to gather knowledge on prognostic factors for neonatal outcome, which is essential for prenatal counseling."

INTRODUCTION {#uog20260-sec-0007}
============

Congenital heart defects (CHD) occur in 5--8 per 1000 live births[1](#uog20260-bib-0001){ref-type="ref"}. Neurodevelopmental impairment (NDI) occurs in a significant number of these children and was originally attributed to cardiothoracic surgery in infancy[2](#uog20260-bib-0002){ref-type="ref"}, [3](#uog20260-bib-0003){ref-type="ref"}, [4](#uog20260-bib-0004){ref-type="ref"}, [5](#uog20260-bib-0005){ref-type="ref"}. Abnormalities on neurological imaging prior to surgery, however, suggested that preoperative factors may influence brain development in neonates with CHD[6](#uog20260-bib-0006){ref-type="ref"}, [7](#uog20260-bib-0007){ref-type="ref"}, [8](#uog20260-bib-0008){ref-type="ref"}. This raised the question as to whether circulatory changes *in utero*, caused by the CHD, could be responsible for the neurological abnormalities seen on preoperative imaging.

To study brain development *in utero*, several cohort studies have reported on head circumference (HC) as a proxy for neurocognitive outcome[9](#uog20260-bib-0009){ref-type="ref"}, [10](#uog20260-bib-0010){ref-type="ref"}, [11](#uog20260-bib-0011){ref-type="ref"}, [12](#uog20260-bib-0012){ref-type="ref"}, [13](#uog20260-bib-0013){ref-type="ref"}, [14](#uog20260-bib-0014){ref-type="ref"}, [15](#uog20260-bib-0015){ref-type="ref"}, [16](#uog20260-bib-0016){ref-type="ref"}, [17](#uog20260-bib-0017){ref-type="ref"}, [18](#uog20260-bib-0018){ref-type="ref"}, [19](#uog20260-bib-0019){ref-type="ref"}, [20](#uog20260-bib-0020){ref-type="ref"}, [21](#uog20260-bib-0021){ref-type="ref"}, as fetal head size is related directly to brain volume. These studies reported a lower mean HC in fetuses and neonates with CHD, particularly in those with hypoplastic left heart syndrome and transposition of the great arteries, compared to the average in the general population[10](#uog20260-bib-0010){ref-type="ref"}, [13](#uog20260-bib-0013){ref-type="ref"}, [18](#uog20260-bib-0018){ref-type="ref"}, [20](#uog20260-bib-0020){ref-type="ref"}. However, our recent, large cohort study, which made several antenatal HC measurements in cases with isolated CHD, could not replicate these results, finding only small differences in fetal head growth, with HC values that remained within the normal range, irrespective of alterations in aortic flow or saturation[12](#uog20260-bib-0012){ref-type="ref"}. Two more recent, large cohort studies also opposed the hypothesis of decreased oxygenation as an explanation for smaller HC, and showed very small differences in HC between normal and CHD fetuses[15](#uog20260-bib-0015){ref-type="ref"}, [17](#uog20260-bib-0017){ref-type="ref"}. A noteable finding was that small changes in HC size were also encountered in cases with a type of CHD that does not result in fetal circulatory changes[15](#uog20260-bib-0015){ref-type="ref"}.

As the latter studies were unable to confirm the hypothesis of diminished fetal head growth in CHD as a result of altered fetal hemodynamics, we hypothesized that genetic effects that remained undetected in pregnancy or placental factors could play a role. To test this hypothesis, as suggested in a referee commentary[22](#uog20260-bib-0022){ref-type="ref"} on our previous study[12](#uog20260-bib-0012){ref-type="ref"}, we retrieved from our regional registry, PRECOR, data on all fetuses with CHD, with the aim of comparing head growth patterns in fetuses with isolated *vs* those with non‐isolated CHD, in order to explore if additional morbidity could explain the reduced head size found in neonates with CHD.

METHODS {#uog20260-sec-0008}
=======

This cohort study used data from three tertiary care centers in Amsterdam and Leiden: Amsterdam University Medical Centers, Amsterdam (two separate locations) and Leiden University Medical Center, Leiden. These centers collaborate in the care of children with CHD within 'CAHAL', the Center for Congenital Heart Disease Amsterdam‐Leiden. CAHAL\'s fetal and neonatal registry is PRECOR; data collection for this registry has been described previously[23](#uog20260-bib-0023){ref-type="ref"}. From PRECOR, we extracted all CHD cases diagnosed prenatally from January 2002 to July 2014, which corresponds with the timeframe of the isolated cases assessed in our previous study[12](#uog20260-bib-0012){ref-type="ref"}. Not eligible for inclusion were subjects with functional CHD or primary arrhythmia with normal cardiac anatomy, and those in multiple pregnancy or with coexisting factors that are a clear cause of altered fetal head growth, such as trisomy 13 or 18, or that show an increase in fetal growth in general, such as maternal diabetes. Subjects with a severe structural brain anomaly that influences fetal head size in itself, such as hydrocephaly or holoprosencephaly, were not included. We also excluded cases in which fetal HC measurements were not available.

Fetal databases and pediatric files in the three centers were used for retrieval of data for all CHD cases, both isolated and non‐isolated. We collected data regarding fetal biometry, pre‐ and postnatal cardiac findings, extracardiac abnormalities, results of genetic tests (duplications/deletions/specific gene panels), maternal information (medical and obstetric history, body mass index (BMI)) and pregnancy outcome. Gestational age was determined by first‐trimester dating scan. Biometric measurements (HC and abdominal circumference (AC)) had been entered into the fetal databases prospectively, as they were part of standard fetal monitoring and therefore measured routinely. All measurements were performed according to the guidelines of the Dutch Society for Obstetrics and Gynecology[24](#uog20260-bib-0024){ref-type="ref"}, which are in concordance with those described by the International Society of Ultrasound in Obstetrics and Gynecology.

Data regarding postnatal cardiac diagnosis and follow‐up of these CHD cases were gathered from the pediatric files. Confirmation of the CHD was based on postnatal echocardiography or postmortem examination. In cases of pregnancy termination without permission for autopsy, the cardiac diagnosis was based on prenatal echocardiography. High compliance between pre‐ and postnatal diagnosis in these centers, as a result of close collaboration between fetal specialists and pediatric cardiologists, has been demonstrated[25](#uog20260-bib-0025){ref-type="ref"}. We retrieved complete follow‐up for all liveborn cases until at least the age of 1 year. Genetic alterations or results of the assessment of a clinical geneticist, as well as extracardiac anomalies diagnosed postnatally, are included in the registry.

Cases were separated into isolated and non‐isolated CHD groups according to the existence of additional morbidity. Isolated CHD was defined as the absence of genetic anomaly, extracardiac malformation and intrauterine growth restriction (IUGR)[12](#uog20260-bib-0012){ref-type="ref"}. If genetic testing was not performed, but cases did not present with additional structural malformations or signs of placental insufficiency, they were allocated to the isolated group. Minor additional findings, such as soft markers, amniotic‐fluid pathology, mild pericardial effusion and/or single umbilical artery were not considered to be a significant structural malformation[12](#uog20260-bib-0012){ref-type="ref"}. As the original isolated cohort described by Jansen *et al*.^12^ did not include subjects from the Amsterdam University Medical Centers in the last 2.5 years, and these cases became available by data extraction from PRECOR, we supplemented the original isolated cohort of 436 cases with these subjects. Both isolated and non‐isolated subjects were clustered according to the expected effect of their CHD on both aortic flow and oxygenation to the brain, based on theoretical hemodynamics, as described in our previous study[12](#uog20260-bib-0012){ref-type="ref"}. A list of diagnoses assigned to each category is given in [Appendix S1](#uog20260-supitem-0001){ref-type="supplementary-material"}.

The non‐isolated group was also further subdivided into three groups: cases with specific genetic alterations or evident dysmorphic features ('genetic‐diagnosis group'); cases with significant extracardiac malformations but without a genetic diagnosis after consultation with a clinical geneticist ('extracardiac‐malformation group'); and cases with maternal complications associated with placental pathology, including IUGR, pre‐eclampsia, hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome and hemolytic uremic syndrome (HUS) ('placental‐pathology group'). Cases with combined pathology, which could be allocated to more than one group, were excluded from the subgroup analysis. For example, a case with 22q11 syndrome and mild pre‐eclampsia was considered non‐isolated, but was not allocated to any of the three subgroups. IUGR was defined as postnatal birth weight \< 3^rd^ percentile, based on national postnatal birth‐weight charts in term subjects[26](#uog20260-bib-0026){ref-type="ref"}. Preterm infants were considered IUGR if either the fetal AC or the estimated fetal weight (EFW) was \< 3^rd^ centile or the AC or EFW was \< 10^th^ centile in combination with abnormal Doppler measurements in the umbilical artery at the last ultrasound scan prior to birth. These cut‐offs were chosen as the postnatal birth‐weight charts in our country do not exclude children who underwent planned preterm delivery due to IUGR or pre‐eclampsia, resulting in charts with overrepresentation of pathology. Pre‐eclampsia was defined as gestational blood pressure elevation (\> 140 mmHg systolic or \> 90 mmHg diastolic) combined with proteinuria (\> 0.3 g/24 h, 30 mg/dL or + 1 on dipstick). The Tennesee classification was used to define HELLP syndrome[27](#uog20260-bib-0027){ref-type="ref"}. To analyze centiles for both AC and EFW with advancing gestation, we used the growth curves of Verburg *et al*.^24^ and Hadlock *et al*.[28](#uog20260-bib-0028){ref-type="ref"}.

Data analysis {#uog20260-sec-0009}
-------------

The distribution of several factors that have the ability to affect fetal growth, such as maternal obesity and smoking, were compared at baseline in the isolated and non‐isolated CHD groups. These two groups were also evaluated for differences in the distribution of types of CHD, with regards to their expected effect on aortic flow and saturation. We compared mean HC *Z*‐scores at 20 weeks' gestation and fetal head growth with advancing gestation (slope of the regression) between isolated and non‐isolated CHD subjects. When there were significant differences between the two groups present at baseline, mean HC and AC *Z*‐scores were corrected for these factors. These outcome parameters were also evaluated for all non‐isolated subgroups separately, compared to reference curves of the standard population[24](#uog20260-bib-0024){ref-type="ref"}. The independent effect of type of comorbidity and other variables of interest on HC *Z*‐scores was assessed amongst non‐isolated CHD subjects by performing a multivariate regression analysis. We examined these data at around 20 weeks\' gestation, as biometric data were available in most cases around this time.

To evaluate the effect of alterations in the intrauterine environment on head growth in CHD cases, we also estimated the expected mean HC *Z*‐score at 36 weeks, as any effect is likely to be most evident in the last few weeks prior to birth. This was corrected for maternal age and based on the mean HC *Z*‐score at 20 weeks and fetal head growth with advancing gestation. AC was also evaluated to relate fetal head size to intrauterine body growth.

Differences in characteristics at baseline were tested with an independent *t*‐test for numerical data, while a χ^2^‐test was performed for all categorical variables. Biometric data (HC and AC) were converted into *Z*‐scores to adjust for the effect of gestational age on fetal growth and to be able to relate the values observed in the dataset to those of the normal population. The growth charts by Verburg *et al*. were used to calculate *Z*‐scores, as they included a large Dutch cohort selected over a similar period of time and these charts have been validated for the Dutch population[24](#uog20260-bib-0024){ref-type="ref"}, [29](#uog20260-bib-0029){ref-type="ref"}. In order to evaluate HC *Z*‐scores amongst isolated and non‐isolated subjects according to advancing gestation and to account for the dependency between repeated measurements, we used a mixed linear regression model with a random intercept and, if data allowed, random slope. This was necessary, as fetal biometry was measured multiple times within the same cases and the interval between the measurements could differ between cases. If data on a variable of interest were missing for \> 10% of the cases, the variable was not included in the multivariate analysis. *P* \< 0.05 was considered to be statistically significant. IBM SPSS statistics version 23.0 (IBM Corp., Armonk, NY, USA) was used for statistical analysis.

RESULTS {#uog20260-sec-0010}
=======

Case selection {#uog20260-sec-0011}
--------------

In total, we extracted from the PRECOR registry 1387 fetuses diagnosed with CHD over the study period. We excluded 64 cases with functional cardiac disease or normal cardiac anatomy on the postnatal scan, 113 cases of multiple pregnancy, 26 with maternal diabetes, 26 with structural congenital brain anomalies and 182 with trisomy 13 or 18 or triploidy. A further 60 were excluded because the HC measurements had not been recorded, of which 44 underwent termination of pregnancy (TOP) before 17 weeks, seven underwent TOP immediately after fetal echocardiography without routine obstetric measurements in the second trimester, eight were referrals near term in which HC measurements were technically impossible due to the head being deeply engaged and one case with ventricular septal defect was referred back to a local hospital after a single fetal echo without obstetric measurements. Thus, after exclusion of 471 cases, there were 916 cases eligible for analysis (Figure [1](#uog20260-fig-0001){ref-type="fig"}).

![Flowchart summarizing cases included in, and excluded from, study cohort of fetuses with congenital heart defect (CHD).](UOG-55-217-g001){#uog20260-fig-0001}

Characteristics of study subjects {#uog20260-sec-0012}
---------------------------------

Of the 916 cases analyzed, 538 had no additional pathology and were classified in the isolated CHD group; of these, 436 have been described previously[12](#uog20260-bib-0012){ref-type="ref"}. In 59.9% of all isolated CHD cases, pre‐ or postnatal karyotyping was performed, confirming the absence of chromosomal abnormalities. In most cases, clinical genetic assessment or type of heart defect was the reason for karyotyping. Of the 378 cases with non‐isolated CHD, five had combined pathology that meant they could be classified into both the genetic‐diagnosis and the placental‐pathology subgroups, and so were excluded from further subgroup analysis. These comprised three cases with (mild) pre‐eclampsia and 22q11 syndrome, one with (mild) pre‐eclampsia and mosaic trisomy 12 and one with severe HELLP syndrome and trisomy 21. The remaining 373 cases with non‐isolated CHD included 213 with a chromosomal or genetic disorder, such as trisomy 21 or 22q11 syndrome, 124 with extracardiac malformation and 36 with placental pathology. There were 177 subjects with a genetic diagnosis and coexisting extracardiac malformation, all of which were included in the genetic‐diagnosis group, because the extracardiac malformations were always part of the genetic diagnosis.

Maternal age and BMI differed significantly between the isolated CHD and non‐isolated CHD groups; mothers of subjects in the non‐isolated CHD group were older (difference between means = 0.9 years) and more of them had BMI \> 25 kg/m^2^ (difference = 10%) (Table [1](#uog20260-tbl-0001){ref-type="table"}). We corrected for maternal age in all subsequent analyses. As BMI was not available in 44% of the subjects, we decided not to correct for BMI. A list of the CHD diagnoses in each of the two groups is given in [Appendix S2](#uog20260-supitem-0001){ref-type="supplementary-material"}. The CHDs in the isolated compared with the non‐isolated CHD group comprised more defects that, theoretically, result in low saturation levels (8.4% *vs* 1.3%; *P* \< 0.001) (Table [2](#uog20260-tbl-0002){ref-type="table"}). The proportion of CHDs that lead to reversed (17.5% *vs* 11.9%; *P* = 0.02) or obstructed (17.7% *vs* 10.6%; *P* = 0.003) aortic flow was also higher in the isolated compared with the non‐isolated CHD cases. CHDs that cause intracardiac mixing, but do not lead to obstructed aortic flow, such as tetralogy of Fallot and pulmonary atresia with ventricular septal defect, were encountered more often amongst the non‐isolated CHD cases (57.9% *vs* 33.5%; *P* \< 0.001) (Table [2](#uog20260-tbl-0002){ref-type="table"}), as these defects are known to be associated with genetic defects.

###### 

Baseline characteristics of pregnancies with fetal congenital heart defect (CHD), according to whether this was isolated

  Characteristic           Isolated CHD (*n* = 538)   Non‐isolated CHD (*n* = 378)   *P*
  ----------------------- -------------------------- ------------------------------ ------
  Fetal HC measurements                                                             
  Total (*n*)                        1556                         1044              
  Mean *n* per case                  2.9                          2.8               
  Maternal age (years)           30.4 ± 5.04                  31.3 ± 5.70            0.02
  Parity                                                                            
  Nulliparous                   235/535 (43.9)               145/378 (38.4)          0.09
  Parous                        300/535 (56.1)               233/378 (61.6)         
  Maternal BMI                                                                      
  ≤ 25 kg/m^2^                  210/314 (66.9)               115/202 (56.9)          0.02
  \> 25 kg/m^2^                 104/314 (33.1)               87/202 (43.1)          
  Smoking                                                                           
  Non‐smoker                    420/464 (90.5)               303/342 (88.6)          0.38
  Smoker                         44/464 (9.5)                39/342 (11.4)          
  Pregnancy outcome                                                                 
  Live birth                    373/538 (69.3)               169/378 (44.7)         
  TOP                           153/538 (28.4)               164/378 (43.4)         
  IUFD                           12/538 (2.2)                45/378 (11.9)          

Data are given as *n*/*N* (%) or mean ± SD unless stated otherwise.

*P* \< 0.05 considered statistically significant.

BMI, body mass index; HC, head circumference; IUFD, intrauterine fetal demise; TOP, termination of pregnancy.

###### 

Distribution of congenital heart defects (CHD) in study population, with regards to their expected effect on aortic flow and oxygenation to brain, for isolated and non‐isolated cases

  Parameter                 Isolated CHD (*n* (%))   Non‐isolated CHD (*n* (%))   Total (*n* (%))   Difference[\*](#uog20260-note-0002a){ref-type="fn"} (95% CI) (%)  *P*
  ------------------------ ------------------------ ---------------------------- ----------------- ------------------------------------------------------------------ ----------
  Oxygenation                                                                                                                                                         
  Low                              45 (8.4)                   5 (1.3)                50 (5.5)                              7.1 (4.35 to 9.79)                         \< 0.001
  Mixed                           314 (58.4)                 281 (74.3)             595 (65.0)                         --16.0 (--21.88 to --9.79)                     \< 0.001
  Normal                          179 (33.3)                 92 (24.3)              271 (29.6)                            8.9 (2.96 to 14.69)                         0.004
  Aortic flow                                                                                                                                                         
  Reversed                        94 (17.5)                  45 (11.9)              139 (15.2)                            5.6 (0.86 to 10.06)                         0.02
  Obstructed                      95 (17.7)                  40 (10.6)              135 (14.7)                            7.1 (2.47 to 11.46)                         0.003
  Normal                          349 (64.9)                 293 (77.5)             642 (70.1)                         --12.6 (--18.33 to --6.70)                     \< 0.001
  Aortic flow reversed                                                                                                                                                
  Oxygenation mixed               94 (17.5)                  45 (11.9)              139 (15.2)                            5.6 (0.86 to 10.06)                         0.02
  Aortic flow obstructed                                                                                                                                              
  Oxygenation mixed                40 (7.4)                   17 (4.5)               57 (6.2)                             2.9 (--0.26 to 5.97)                        0.07
  Oxygenation normal              55 (10.2)                   23 (6.1)               78 (8.5)                              4.1 (0.46 to 7.62)                         0.03
  Aortic flow normal                                                                                                                                                  
  Oxygenation low                  45 (8.4)                   5 (1.3)                50 (5.5)                              7.1 (4.35 to 9.79)                         \< 0.001
  Oxygenation mixed               180 (33.5)                 219 (57.9)             399 (43.6)                        --24.5 (--30.69 to --17.99)                     \< 0.001
  Oxygenation normal              124 (23.1)                 69 (18.3)              193 (21.1)                            4.8 (--0.59 to 9.97)                        0.10

*P* \< 0.05 considered statistically significant.

Isolated minus non‐isolated result.

The mean HC *Z*‐score was significantly lower in the non‐isolated CHD cohort (Z‐score = --0.70 (95% CI, --0.84 to --0.55)) compared with the isolated CHD cohort (*Z*‐score = --0.03 (95% CI, --0.15 to 0.10)) at 20 weeks (*P* \< 0.001) (Table [3](#uog20260-tbl-0003){ref-type="table"}). The reduction in head growth with advancing gestation was significantly greater in the non‐isolated CHD cases (change in HC *Z*‐score of --0.03 *vs* --0.01 per week; *P* = 0.01). The estimated expected mean HC *Z*‐score at 36 weeks was --1.22 (95% CI, --1.45 to --0.98) for non‐isolated CHD cases and --0.19 (95% CI, --0.36 to --0.01) for isolated CHD cases, which means both estimates still lay within the limits of normality. AC *Z*‐scores were also significantly lower in non‐isolated CHD fetuses, with a mean AC *Z*‐score of --0.47 compared with --0.02 in isolated CHD cases (*P* \< 0.001), and a change in AC *Z*‐score of −0.02 per week in non‐isolated *vs* change of + 0.01 per week in isolated cases at 20 weeks (*P* = 0.001) (Figure [2](#uog20260-fig-0002){ref-type="fig"}).

###### 

Head circumference (HC) and abdominal circumference (AC) *Z*‐scores in isolated and non‐isolated cases of fetal congenital heart defect (CHD)

                                                          GA 36 weeks[†](#uog20260-note-0005){ref-type="fn"}                                                            
  --------------------------- --------------------------- ---------------------------------------------------- --------- ---------------------------------------------- ---------------------------
  HC *Z*‐score                                                                                                                                                          
  Isolated CHD                  --0.03 (--0.15 to 0.10)   \< 0.001[‡](#uog20260-note-0006){ref-type="fn"}      --0.010    0.01[‡](#uog20260-note-0006){ref-type="fn"}    --0.19 (--0.36 to --0.01)
  Non‐isolated CHD             --0.70 (--0.84 to --0.55)                                                       --0.032                                                   --1.22 (--1.45 to --0.98)
  Genetic diagnosis            --0.73 (--0.95 to --0.50)  \< 0.001[§](#uog20260-note-0007){ref-type="fn"}      --0.037                                                   --1.32 (--1.79 to --0.86)
  Extracardiac malformation    --0.49 (--0.80 to --0.17)  0.002[§](#uog20260-note-0007){ref-type="fn"}         --0.023                                                   --0.85 (--1.38 to --0.32)
  Placental pathology          --1.29 (--1.97 to --0.61)  \< 0.001[§](#uog20260-note-0007){ref-type="fn"}      --0.057                                                   --2.20 (--3.30 to --1.10)
  AC *Z*‐score                                                                                                                                                          
  Isolated CHD                  --0.02 (--0.15 to 0.10)   \< 0.001[‡](#uog20260-note-0006){ref-type="fn"}       0.012     0.001[‡](#uog20260-note-0006){ref-type="fn"}     0.16 (--0.03 to 0.34)
  Non‐isolated CHD             --0.47 (--0.61 to --0.32)                                                       --0.020                                                   --0.79 (--1.04 to --0.54)
  Genetic diagnosis            --0.47 (--0.69 to --0.26)  \< 0.001[§](#uog20260-note-0007){ref-type="fn"}      --0.016                                                   --1.30 (--1.76 to --0.84)
  Extracardiac malformation     --0.25 (--0.62 to 0.11)   0.17[§](#uog20260-note-0007){ref-type="fn"}           0.002                                                     --0.22 (--1.11 to 0.68)
  Placental pathology          --1.24 (--1.84 to --0.63)  \< 0.001[§](#uog20260-note-0007){ref-type="fn"}      --0.071                                                   --2.37 (--3.03 to --1.72)

All values depicted were corrected for maternal age.

*P* \< 0.05 considered statistically significant.

Mean *Z*‐scores and slopes calculated from biometric data.

Mean *Z*‐scores and slopes estimated using mixed linear regression model with gestational age (GA) centered at 20 weeks.

Isolated *vs* non‐isolated groups.

Mean HC *Z*‐score for subgroups compared separately with normal growth reference[24](#uog20260-bib-0024){ref-type="ref"} (mean *Z* = 0).

![Head (a,c,e) and abdominal (b,d,f) growth trajectories of fetuses with congenital heart defect (CHD): (a,b) in all cases, according to whether CHD was isolated (cyan) or non‐isolated (magenta); (c--f) in non‐isolated CHD cases, subdivided according to additional pathology (red, genetic anomaly; green, extracardiac malformation; blue, placental pathology). Solid lines are mean and dotted lines are 95% CI. AC, abdominal circumference; HC, head circumference.](UOG-55-217-g002){#uog20260-fig-0002}

Subgroup analysis {#uog20260-sec-0013}
-----------------

Of the 213 non‐isolated CHD subjects in the genetic‐diagnosis group, 143 were diagnosed with a chromosomal anomaly, including trisomy 21 (*n* = 102), Turner syndrome (*n* = 20), mosaic variegated aneuploidy syndrome (*n* = 3), unbalanced translocation (*n* = 14) and other chromosomal anomaly (*n* = 4). The other 70 subjects had a genetic diagnosis, including 22q11.2 microdeletion syndrome (*n* = 27), CHARGE syndrome (*n* = 4), VACTERL association (*n* = 4), Noonan syndrome (*n* = 3), another miscellaneous genetic syndrome (*n* = 15), duplication (*n* = 8), deletion \> 5 Mb on array comparative genomic hybridization (*n* = 7), or a strong clinical suspicion for a specific genetic syndrome without further diagnostic tests (*n* = 2). Significant extracardiac abnormalities were encountered in 124 subjects without a genetic diagnosis or dysmorphic features (extracardiac‐malformation group). The 36 subjects presenting with placental pathology resulting in impaired fetal growth (placental‐pathology group) included subjects with pre‐eclampsia (*n* = 8), HELLP (*n* = 2), HUS (*n* = 1) and IUGR without maternal disease (*n* = 25).

We evaluated the HC *Z*‐scores, corrected for maternal age, for these three subgroups separately (Table [3](#uog20260-tbl-0003){ref-type="table"}). All three subgroups showed a reduction in HC compared to the normal growth charts[24](#uog20260-bib-0024){ref-type="ref"}. Subjects with a genetic anomaly had a mean HC *Z*‐score at 20 weeks of --0.73 (*P* \< 0.001) and an estimated *Z*‐score at 36 weeks of --1.32. The extracardiac‐malformation group had a mean HC *Z*‐score at 20 weeks of --0.49 (*P* = 0.002) and an estimated *Z*‐score at 36 weeks of --0.85. The placental‐pathology group showed the greatest negative effect on fetal HC; the mean HC *Z*‐score at 20 weeks in this group was --1.29 (*P* \< 0.001), which decreased further to an estimated HC *Z*‐score of --2.20 at 36 weeks. The mean AC *Z*‐scores for each subgroup are presented in Table [3](#uog20260-tbl-0003){ref-type="table"}.

Multivariate analysis {#uog20260-sec-0014}
---------------------

The multivariate analysis to evaluate the influence of type of comorbidity, maternal age, smoking and being parous on mean HC *Z*‐score and intrauterine fetal head growth at 20 weeks in all non‐isolated CHD subjects is summarized in Table [4](#uog20260-tbl-0004){ref-type="table"}. Corrected for the other variables of interest, the presence of placental pathology, smoking and being parous appeared to be significant independent risk factors for a lower HC *Z*‐score at 20 weeks\' gestation. Additional pathology and being parous also tended to have a negative effect on head growth progression (slope) at 20 weeks.

###### 

Multivariate analysis to estimate influence of comorbidity and possible confounders on fetal head circumference (HC) at 20 gestational weeks in 373 fetuses (1031 HC measurements) with non‐isolated congenital heart defect

  Variable                    Fetuses (*n*)   HC measurements (*n*)    Mean HC *Z*‐score (SD)   *P*    Slope (SD/week) (95% CI)   *P*
  --------------------------- --------------- ----------------------- ------------------------ ------ -------------------------- ------
  Type of comorbidity                                                                           0.05                              0.59
  Extracardiac malformation   124             337                            Reference                        Reference          
  Genetic diagnosis           213             531                          --0.33 (0.10)        0.13   --0.02 (--0.07 to 0.03)    0.43
  Placental pathology         36              163                          --0.77 (0.02)        0.02   --0.05 (--0.12 to 0.01)    0.11
  Variable of interest                                                                                                           
  Maternal age (in years)     373             1031                          0.02 (0.32)         0.27   0.001 (--0.003 to 0.004)   0.73
  Smoking (yes)               39              99                           --0.64 (0.02)        0.03    0.01 (--0.05 to 0.08)     0.69
  Parous (yes)                233             647                          --0.56 (0.01)        0.04   --0.02 (--0.06 to 0.03)    0.44

Mean HC *Z*‐scores and slopes estimated using mixed linear regression model with gestational age centered at 20 weeks.

*P* \< 0.05 considered statistically significant.

DISCUSSION {#uog20260-sec-0015}
==========

Fetuses with non‐isolated CHD had a significantly smaller HC at midgestation and more constrained head growth towards the end of pregnancy, compared with fetuses with isolated CHD. Although the mean HC *Z*‐score prior to delivery was --1.2 amongst CHD cases with additional pathology, compared with --0.2 in isolated CHD cases, both estimates still lie within the limits of normality. The decrease in HC appeared most prominent amongst subjects with placenta‐related pathology.

Most studies that have explored fetal HC in CHD compared their findings to head size in normal fetuses[9](#uog20260-bib-0009){ref-type="ref"}, [14](#uog20260-bib-0014){ref-type="ref"}, [15](#uog20260-bib-0015){ref-type="ref"}, [21](#uog20260-bib-0021){ref-type="ref"}, [30](#uog20260-bib-0030){ref-type="ref"}, [31](#uog20260-bib-0031){ref-type="ref"}, [32](#uog20260-bib-0032){ref-type="ref"} and did not strictly exclude non‐isolated cases[11](#uog20260-bib-0011){ref-type="ref"}, [16](#uog20260-bib-0016){ref-type="ref"}, [21](#uog20260-bib-0021){ref-type="ref"}, [30](#uog20260-bib-0030){ref-type="ref"}, [33](#uog20260-bib-0033){ref-type="ref"}, [34](#uog20260-bib-0034){ref-type="ref"}. As our cases originate from a large regional cohort with follow‐up, we were able to analyze differences between non‐isolated and isolated cases, and to test specific subgroups separately, with clustering of specific CHD types. All non‐isolated CHD subgroups showed a significant decrease in head growth compared with normal charts. The largest effect was encountered in fetuses affected by placental pathology, followed by those with a genetic diagnosis and those with an extracardiac malformation. The progressive decline in (head) growth towards the end of pregnancy, encountered in all three subgroups, is a feature of placental insufficiency and characterized by a decrease in the ability to reach a certain growth potential with advancing gestation[35](#uog20260-bib-0035){ref-type="ref"}. This implies that cases with a genetic diagnosis or extracardiac malformation as well as truly isolated cases did not reach their genetic growth potential, despite measurements lying within the limits of normality[36](#uog20260-bib-0036){ref-type="ref"}.

The types of CHD differed significantly between the isolated CHD and the non‐isolated CHD groups. The isolated CHD group, in which HC growth was decreased only minimally, included significantly more CHDs that result in low cerebral oxygenation, such as transposition of the great arteries. CHDs that cause decreased flow towards the brain (e.g. aortic coarctation and hypoplastic left heart syndrome) were also encountered more frequently amongst cases of isolated CHD. Non‐isolated CHD subjects, in which impaired head growth was most pronounced, had mainly CHDs without any hemodynamic effect on aortic flow (e.g. tetralogy of Fallot). If our previously raised hypothesis[12](#uog20260-bib-0012){ref-type="ref"}, that diminished fetal head growth in CHD is a result of altered fetal hemodynamics, is correct, it should have been head growth in the isolated group that was the more severely decreased, but our current findings indicate the opposite. Reduced head size cannot, therefore, be attributed to altered cerebral hemodynamics.

Recent studies support that both growth restriction (17--18%) and placenta‐related complications, such as pre‐eclampsia, occur more frequently in CHD cases[15](#uog20260-bib-0015){ref-type="ref"}, [36](#uog20260-bib-0036){ref-type="ref"}, [37](#uog20260-bib-0037){ref-type="ref"}, [38](#uog20260-bib-0038){ref-type="ref"}, [39](#uog20260-bib-0039){ref-type="ref"}, [40](#uog20260-bib-0040){ref-type="ref"}, [41](#uog20260-bib-0041){ref-type="ref"}. However, as previous studies reporting on HC in CHD did not look at birth weight, growth trajectories or additional genetic pathology, their findings may, in our opinion, be explained by additional pathology.

As all three non‐isolated CHD subgroups in our study showed some form of growth restriction, it is possible that a common factor, involving both the development of CHD and the placenta, could play a role. The levels of (anti‐)angiogenetic markers, including placental growth factor (PlGF), soluble fms‐like tyrosine kinase‐1 (sFlt‐1), vascular endothelial growth factor (VEGF) and other factors associated with chronic hypoxia, are altered (increased or decreased) in CHD subjects[42](#uog20260-bib-0042){ref-type="ref"}, [43](#uog20260-bib-0043){ref-type="ref"}. These factors have been proven to be related to embryonic and cardiac development as well[44](#uog20260-bib-0044){ref-type="ref"}, [45](#uog20260-bib-0045){ref-type="ref"}, [46](#uog20260-bib-0046){ref-type="ref"}, [47](#uog20260-bib-0047){ref-type="ref"}, [48](#uog20260-bib-0048){ref-type="ref"}, [49](#uog20260-bib-0049){ref-type="ref"}, and overexpression has been shown to result in abnormal heart development[47](#uog20260-bib-0047){ref-type="ref"}, [50](#uog20260-bib-0050){ref-type="ref"}. Lower oxygen saturation levels in the umbilical vein[42](#uog20260-bib-0042){ref-type="ref"}, [43](#uog20260-bib-0043){ref-type="ref"} and increased resistance in the umbilical artery[19](#uog20260-bib-0019){ref-type="ref"}, which are additional signs of impaired placental function, have also been reported in CHD pregnancies. This angiogenic imbalance is also encountered in placental tissue derived from IUGR fetuses[51](#uog20260-bib-0051){ref-type="ref"}. Altered levels of PlGF and sFlt‐1 have been shown to be associated with a higher risk for IUGR and developing pre‐eclampsia[52](#uog20260-bib-0052){ref-type="ref"}, [53](#uog20260-bib-0053){ref-type="ref"}, [54](#uog20260-bib-0054){ref-type="ref"}. This similarity of antiangiogenic environment in subjects with CHD and those with IUGR implies that the pathophysiology of both diseases might share a common pathway[36](#uog20260-bib-0036){ref-type="ref"}, [47](#uog20260-bib-0047){ref-type="ref"}.

Furthermore, it seems that (head) growth restriction is linked to specific CHDs[12](#uog20260-bib-0012){ref-type="ref"}, [15](#uog20260-bib-0015){ref-type="ref"}, [36](#uog20260-bib-0036){ref-type="ref"}, [55](#uog20260-bib-0055){ref-type="ref"}, [56](#uog20260-bib-0056){ref-type="ref"}. Differences in the VEGF signalling pathway have been shown to affect endocardial cushion formation and septation of the cardiac chambers, and may result in aberrant aortic arch artery patterning and outflow tract anomalies[47](#uog20260-bib-0047){ref-type="ref"}, [57](#uog20260-bib-0057){ref-type="ref"}, [58](#uog20260-bib-0058){ref-type="ref"}. Future research should assess large cohorts and, if available, biobanks, to explore this further. The findings in our cohort highlight that future studies on fetal (brain) development should not be undertaken without analysis of fetal growth and additional morbidity.

As head growth is multifactorial and the direct relationship with neurodevelopmental outcome has not yet been studied in strictly isolated cases[11](#uog20260-bib-0011){ref-type="ref"}, [21](#uog20260-bib-0021){ref-type="ref"}, it is debatable whether HC should be used as a proxy. It was found that decreased somatic growth, rather than head growth, might be an important predictor for NDI in a group with specific types of CHD[11](#uog20260-bib-0011){ref-type="ref"}, [21](#uog20260-bib-0021){ref-type="ref"}. Results of a recent Dutch cohort support this, as a smaller AC and lower EFW were risk factors for NDI, whereas HC alone was not[59](#uog20260-bib-0059){ref-type="ref"}.

A limitation of our study is the fact that the biometric data were not distributed equally throughout pregnancy in non‐isolated compared with isolated CHD cases, due to the higher incidence of TOP and intrauterine fetal demise in the non‐isolated CHD group. Furthermore, genetic testing was not performed in several cases for the same reason. Although completeness of data is rarely possible in retrospective cohorts, information was available in a significant proportion of cases, as follow‐up was complete until at least 1 year of age. The current literature lacks information on the impact of additional pathology, as this has not, to our knowledge, been studied before in such a large cohort.

Our results show that the presence of additional pathology has a large effect on head growth in fetuses with CHD, which is more pronounced than the effect of aortic flow or saturation in these cases. The factor contributing most seems to be abnormal placentation, although genetic anomaly also plays an important role. Pathways involved in both the development of CHD and fetal growth appear to influence head growth more than does the CHD itself. Future research on brain development in CHD fetuses and infants should, therefore, relate to overall growth and additional pathology.
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**Appendix S1** Distribution of individual, prenatal‐ultrasound diagnoses, based on their effect on oxygen delivery to brain and flow through aortic arch, in cases of isolated and of non‐isolated congenital heart defect

**Appendix S2** List of primary diagnoses per group (as confirmed postnatally), based on their proportion within this cohort and risk for additional pathology

###### 

Click here for additional data file.
